VERU trade ideas
VERU log chart. Wedge within a megaphone and channel.This is a mighty COVID treatment play. It's a coin flip whether it will break up or down out of the blue dashed wedge, but when it does. . . there are many place it can go. Options prices remain elevated even for $10 strikes (around the lower ascending channel). All depends on the Phase III trial data and analysis.
Personally, I bought 1000 shares in the February pullback before the mega rally, sold into strength, and still hold 150. I've been selling $10, $15 and $17.5 strike weekly puts and taking profits at 50% to 75%. I will take any long red candles as an opportunity to sell lower-strike puts.
So my bias is long, but to sell into strength. Caveat emptor.
VERU: Bullish PennantBullish Pennant
Pros:
Descending volume during formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 6
200MA ascending, but barely
250RSI above 50
Target:
PT = 35.90$
$VERU - Push past $10 tomorrow?If $VERU can close above this volume shelf I can see it getting to $10+ tomorrow. Already in it. My cost basis = $9.00 - Target $12 plus.
Stock to watch: Veru Inc (NASDAQ: VERU)NASDAQ:VERU
An interesting stock to watch.
The asset is in a 1,5 month uptrend without major pullbacks + MACD Crossover indicator's Long signal is still in progress.
The buy zone is marked out, targets are 12.5, 15, 18, 23,88 and towards the all-time high.
Invalidation: closing below the gap.
Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.
Bullish pennant. VERU is consolidating and i am liking this chart alot. The MACD is in red still and will wait to get in once i see the MACD closing red. Give this a week to play out. Not a financial advisor.
VERUClean test of the 5 sma & gap fill. Resistance line goes back to 1991. Could get moving if it breaks.
$VERU Inc Making Move To ATH
VerU finally made its move today,
tomorrow we will look for a move above the Fibonacci Golden pocket @ $10.16
Target is back to the ATH @ $11.45
Potential resistance $10.98
$VERU Inc GAp Up reversal Trade
VERU may offer the potential for a reversal trade as it
bounces off GAP up and Yearly candle support.
MA's have caught to provide support.
Selling volume has declined considerably.
The pumpers and misguided late comers may have exited.
Potential entry above $9.15
Targets as per Fibonacci retracement levels.
VERU (breast cancer treatment) calendar spread ideaVERU is an oncology bio pharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer. It announced the presentation of pre-clinical data demonstrating the efficacy of oral VERU-111 in the treatment of human derived animal models of triple negative breast cancer. VERU reported on 12/9/20 Q4 earnings loss of $0.01 per share on revenue of $11.7 million. The consensus estimate was a loss of $0.05 per share on revenue of $10.6 million. That's a +80% eps surprise. Revenue grew 34.6% on a year-over-year basis.
This is a speculative risky play. My idea is a VERU calendar spread:
buy $10 call 1/15/21
sell $12.50 call 12/18
The worst thing that could happen this week would be a credit of $250 per spread on 12/18. Otherwise, your risk is $145 till 1/15/21. Or you can simply dca shares each day this week according to your indicators.
Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny / a day, for a month it = $5,368,709. Good luck and happy trading friends...
*3x lucky 7s of trading*
7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet
7 Common mistakes:
+5% portfolio trades, risk management
Beware of analysts motives
Emotions & Opinions
FOMO : bad timing
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation
7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big organized desk
Reading books, playing chess
Sorted watch-list
Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
www.tradingview.com
$VERU Cup & Handle Company details
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
$VERU - Bullish Trend Good YTD So FarVeru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
SHORT INTEREST
52.79K 09/30/19
P/E Current
-4.75
P/E Ratio (with extraordinary items)
-7.87
Average Recommendation: BUY Average Target Price: 7.38
I THINK WE'RE GOING TO SEE SOME NICE ACTION TODAYexpecting to see this make .20 per share today. obviously, let's wait and see. #travisten
